Magle Chemoswed Holding
29,4
SEK
-2 %
Mindre end 1K følgere
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-2%
-5,77%
-15,52%
-15,52%
-23,93%
-8,34%
+2,13%
-
+46,32%
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Læs mereMarkedsværdi
603,17 mio. SEK
Aktieomsætning
23,46 t SEK
Omsætning
236,04 mio.
EBIT %
9,84 %
P/E
0,67
Udbytteafkast, %
-
Finanskalender
26.5
2025
Generalforsamling '25
Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Redeye: Magle Chemoswed Q4 - Delivering on its growth trajectory
Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools